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LYMPHATIC MAPPING AND
SENTINEL LYMPHNODE BIOPSY IN
BREAST CANCER PATIENTS IN
CLlNICAL STAGE T1-T2 NO MO
P. Murawa, M. Mańczak, J. Wasiewicz,
A. Gracz, D. Bręborowicz, J. Malicki
Wielkopolskie Centrum Onkologii, Poznań,
Polska
The authors report the feasibility an aeeuracy
of intraoperative sentinel Iymphnode biopsy
(SLN) in patients with operable breast cancer to
test the hypothesis that the histologie
eharacteristic of SLN predicts the histologie
status of remaining Iymph nodes in the axilla.
In between August 1999 and May 2000 to SLN
biopsy there were 124 patients enrolled with
median age of 55,2 years of age. Ali patients
had operable breast eaneer and all axillary
Iymphnodes were elinieally negative.
A day before surgery 4 ee of Nannoeol marked
with Te99 was injeeted subeutuanesly nearby
the tumor bed and an hour later the
Iymphoseyntygraphy was performed to aehieve
axillary Iymphnodes mapping. Then immediately
prior to surgery Blue Dye Patent Blau V was
injeeted in the same manner as the radiologieal
marker. Then with the use of hand - heJd
gamma probe the hotspot was defined and
marked. Five to ten minutes later first eut was
performed over marked hotspot. After
visualization of stained Iymph vassals the SLN
was traeed and confirmed with high dose output
( using the Neoprobe ) and then was harvested
for histologie examination . After this all patients
were submitted for regular Iymphadeneetomy
regardless main surgery type (masteetomy or
BCT).
Employing above method we were able to
define SLN in 93,3%, only in 6,7% of our
patients identifieation failed. In the group with
defined SLN we found eaneer eells deposits only
in 20 %. And in that group remaining
Iymphnodes had eaneer metastasis in almost 80
%. We had two cases of false negative results
but stil! our speeify rate was over 97 %.
In conclusion we think that SLN biopsy is quite
safe and effieient method to evaluate axillary
Iymphnodes status in patients with operable
early stage breast eaneer. Our findings are also
eonfirmed by other authors world wideo
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HOW OFTEN SHOULD WE OBTAIN
COMPLETE BLOOD COUNTS (CBC's)
FROM PATIENTS RECEIVING
RADICAL RADlATlON THERAPY?
R. Dziadziuszko, K. Sosińska-Mielcarek,
E. Szutowicz-Zielinska, J. Jassem
Medical University ot Gdańsk
Data on factors influeneing deeline in
peripheral blood eounts during radiation
treatment are sparse and no guidelines exist on
the appropriate frequency of obtaining CBC's
from the patients.
Patients and methods: A series of charts
from 460 eonsecutive patients receiving
radiotherapy in 1995 and 1996 was reviewed. In
the final database, the data from patients
reeeiving detinitive radiotherapy with information
on baseline CBC's and at least two results
during treatment were included (183 patients,
810 results). Critical nadir values of
haemoglobin (HGB), white blood eells (WBC)
and platelets (PLT) requiring further tests and
interventions were defined as follows: HGB<9.0
g/dL, WBC<2.000/mm3, PLT<1 00/mm3. For
statistical analysis, logistie regression was used
separately for eaeh parameter and then the
prognostie model of obtaining at least one nadir
value in all tests performed in one patient was
developed.
Results: Of183 patients, at least one nadir
value was observed in 17 patients (9%). Pre-
treatment CBC was very strong and the only
predictor of nadirs - the other variabies were not
signifieant in the finał model. The probability of
at least one nadir during treatment was 35% if
one of the following pre-treatment CBC values
was noted: HGB<11.0 g/dL, WBC<5.000/mm3
or PLT<150/mm3. A very low nadir probability of
1.6% was observed in the remaining group of
patients.
Conclusion: Outside clinical triais, monitoring
of CBC's in patients receiving radieal radiation
treatment should be performed ił baseline
values are below the proposed Iimits or other
eytotoxie therapy is given.
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